Predicting the Long-Term Stability of Biologics
Analysis of Formulation-Dependent Colloidal and Conformational Stability of Monoclonal Antibodies
The growing number of biological drugs such as monoclonal antibodies (mAbs), as well as the wealth of heterogeneity between mAb variants requires a thorough development process to maximize mAbs compliance with regulation. Therefore, biophysical analytical methods are required already at early stages of the development process to guide and streamline further antibody processing and to predict antibody developability. In this case study, we demonstrate how the Prometheus NT.48 can be used to predict long-term mAb stability in a formulation screen by simultaneous quantification of both, conformational and colloidal stability of biologicals in thermal gradients.
Download white paper now
Predicting the Long-Term Stability of Biologics
Analysis of Formulation-Dependent Colloidal and Conformational Stability of Monoclonal Antibodies
Advertisement
White Paper classification
You may also be interested in these white papers
See the theme worlds for related content
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous
Last viewed contents
Verifying SPARCL Performance on the CLARIOstar Equipped for Reading at Time of Injection -
Optimizing Protein Purification Conditions -
Streamlining Affinity Analysis for Accelerated Biologics Development and Production - High-throughput and assay versatility for rapid development and qualification of biopharmaceuticals
Optimizing Kinetics Assays to Prevent Avidity Effects - Robust experimental design avoids artefacts in the measurement of binding kinetics and affinity
How to purify and analyze your antibodies efficiently - All the chromatography methods and practical tips to simplify and reduce the costs of your processes
Now ready - Easy Bispecific Antibody Evaluation - Analyze specific binding of bsAbs in addition to IgG titer in a single high-throughput assay
Decoys for Misguided Antibodies Restore Antiviral Immune Defense
Structural basis of the function of therapeutic antibodies in cancer immunotherapy elucidated - New study shows how the single-molecule organization of receptors in the cellular context determines the function of antibodies
Billion-Dollar Deal for Cancer Antibody: BioNTech and Bristol Myers Squibb Join Forces - "...an asset with significant potential for transforming the standard of care for patients with solid tumors"
Memo Therapeutics AG - Schlieren, Switzerland
Biointron Biological Inc. - Metuchen, USA
